Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
Inventors
Buck, Rachael • Thomas, Debra • Schaller, Joseph
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12594288-B2
Publication Date
2026-04-07
Expiration Date
Abstract
Disclosed are nutritional compositions including human milk oligosaccharides and nucleotides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Core Innovation
The invention relates to synthetic pediatric formulas that are shelf stable for at least three months and are provided in the form of a liquid or reconstitutable powder. The synthetic pediatric formula is formulated to reduce inflammation and includes specified nucleotides, specified sialylactose, and at least one of docosahexaenoic acid and arachidonic acid.
The composition includes from about 40 mg/L to about 350 mg/L of at least one of cytidine 5’-monophosphate, uridine 5’-monophosphate, adenosine 5’-monophosphate, guanosine 5’-monophosphate, and combinations thereof. The formula further includes from about 0.01 mg/mL to about 10 mg/mL of at least one of 3’-sialylactose and 6’-sialylactose.
The invention also provides methods for reducing inflammation due to a viral infection in an infant, toddler, or child by administering a shelf stable nutritional composition. The nutritional composition comprises the defined nucleotide monophosphates and the defined sialylactose, and is shelf stable for at least three months.
The described HMO and nucleotide components are associated with reducing virus-induced inflammatory responses while not increasing viral load. The disclosure further reports reduced oxidative stress markers in preterm piglets and decreased rotavirus replication in ileal loop models, including reduced NSP4 expression.
Claims Coverage
The document provides at least two independent claims: a composition claim and a method claim. Across these claims, there are 4 core inventive feature groupings: a shelf-stable synthetic pediatric formula or nutritional composition, a defined combination of nucleotide monophosphates and sialylactose in specified ranges, inclusion of at least one of DHA and ARA in the composition claim, and an inflammation-reduction context tied to viral infection in the method claim.
Shelf stable synthetic pediatric formula for reducing inflammation
A shelf stable synthetic pediatric formula, in the form of a liquid or reconstitutable powder, for reducing inflammation and shelf stable for at least three months.
Defined nucleotide monophosphate content
The synthetic pediatric formula comprises from about 40 mg/L to about 350 mg/L of at least one of cytidine 5’-monophosphate, uridine 5’-monophosphate, adenosine 5’-monophosphate, guanosine 5’-monophosphate, and combinations thereof.
Defined sialylactose content
The synthetic pediatric formula comprises from about 0.01 mg/mL to about 10 mg/mL of at least one of 3’-sialylactose and 6’-sialylactose.
Inclusion of at least one of DHA and ARA
The shelf stable synthetic pediatric formula further comprises at least one of docosahexaenoic acid and arachidonic acid.
Method for reducing inflammation due to viral infection via administration of the shelf stable composition
A method for reducing inflammation due to a viral infection in an infant, toddler, or child in need thereof, the method comprising administering a nutritional composition comprising the defined nucleotide monophosphate content and the defined sialylactose content, wherein the nutritional composition is shelf stable for at least three months.
Overall claim coverage centers on shelf stability for at least three months, a specified combination of nucleotide monophosphates and sialylactose, inclusion of at least one of DHA and ARA in the composition claim, and inflammation reduction tied to viral infection in the method claim.
Stated Advantages
Reducing inflammation.
Reducing inflammation due to a viral infection in an infant, toddler, or child.
Reducing virus-induced inflammatory responses while not increasing viral load.
Reduced oxidative stress markers in preterm piglets.
Decreased rotavirus replication in ileal loop models, including reduced NSP4 expression.
Documented Applications
Reducing inflammation due to a viral infection in an infant, toddler, or child by administering the shelf-stable nutritional composition.
Providing a shelf stable synthetic pediatric formula in liquid or reconstitutable powder form for reducing inflammation.
Addressing enteric and respiratory viral infections in preterm and pediatric populations.
Interested in licensing this patent?